Malignant Glioma Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
Dallas, TX (PRWEB) February 12, 2015 -- The report “Malignant Glioma – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Malignant Glioma. A glioma is a type of malignant brain tumor. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain. There are four main types of glioma are Ependymomas, Astrocytomas, Oligodendrogliomas and Mixed gliomas. Symptoms of glioma emerge slowly and may be small at first. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/malignant-glioma-pipeline-review-h1-2015-market-report.html .
The report also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. Companies discussed in this Malignant Glioma – Pipeline Review, H1 2015 report include Advantagene, Inc., Eli Lilly and Company, iDD biotech SAS, Lipopharma Therapeutics SL, Merck & Co., Inc., Nuo Therapeutics, Inc., Orbus Therapeutics, Inc., Sanofi, Stemline Therapeutics, Inc., ZIOPHARM Oncology, Inc.
The most common symptoms are headaches, seizures, personality changes, weakness in the arms or legs, numbness, nausea, vomiting and vision loss. Drugs profile discussed in this report include Ad-RTS-IL-12, ALD-451, Dendritic Cell Therapy for Malignant Gliomas, Dendritic Cell Therapy for Oncology, eflornithine hydrochloride, galunisertib, GliAtak, IDD-004, LD-224, marizomib, Minerval, Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme, pembrolizumab, SL-701, Small Molecule for Brain Cancer and Malignant Glioma, Vaccine to Target Survivin for Malignant Glioma, Vaccine to Target Wilm's Tumor 1 for Oncology, voxtalisib. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269578 . (This is a premium report priced at US$2000 for a single user License.)
The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Table of content
List of Tables
Number of Products under Development for Malignant Glioma, H1 2015
Number of Products under Development for Malignant Glioma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Malignant Glioma - Pipeline by Advantagene, Inc., H1 2015
Malignant Glioma - Pipeline by Eli Lilly and Company, H1 2015
Malignant Glioma - Pipeline by iDD biotech SAS, H1 2015
Malignant Glioma - Pipeline by Lipopharma Therapeutics SL, H1 2015
Malignant Glioma - Pipeline by Merck & Co., Inc., H1 2015
Malignant Glioma - Pipeline by Nuo Therapeutics, Inc., H1 2015
Malignant Glioma - Pipeline by Orbus Therapeutics, Inc., H1 2015
Malignant Glioma - Pipeline by Sanofi, H1 2015
Malignant Glioma - Pipeline by Stemline Therapeutics, Inc., H1 2015
Malignant Glioma - Pipeline by ZIOPHARM Oncology, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Malignant Glioma Therapeutics - Recent Pipeline Updates, H1 2015
Malignant Glioma - Dormant Projects, H1 2015
Malignant Glioma - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Malignant Glioma, H1 2015
Number of Products under Development for Malignant Glioma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Explore more reports on Cancer Drugs Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs .
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article